I launched and sold Inbrija and have since left. Not only is the market crowded. I think 3-4 new meds launched for PD in the last couple years. Every single one was for patients experiencing OFF episodes. But the real Market dynamic all the company’s failed to account for is Medicare Part D copays. Traditional Medicare not Medicaid or low income subsidized patients. They simply cannot afford the copay for a branded specialty product. And unlike disease states with prices upwards of 100k/yr, the non profit subsidy to help with copays does not exist in PD.